The growing interest in potent weight management has spurred considerable exploration into groundbreaking treatments. Currently, Retatrutide, a combined -action glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor activator , has shown positive results in patient trials, suggesti